Last Updated on November 23, 2022 by GlobeNewsWire
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below:
BTIG Ophthalmology Day
Date:Tuesday, November 29, 2022 Time:1:30 – 1:55 PM ET
The Eyenovia management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Eyenovia at either conference should contact their BTIG representative.
About Eyenovia, Inc.
Eyenovia, Inc. (Nasdaq: EYEN) is a pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Eyenovia Contact:Eyenovia, Inc.John GandolfoChief Financial Officerjgandolfo@eyenovia.com
Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363
Eyenovia Media Contact:Norbert LoweVice President, Commercial OperationsEyenovianlowe@eyenovia.com